Selected studies comparing Aza/VEN with other therapies in AML
| Study . | Trial type . | Aza/VEN response . | Comparator . | Comparator response . | Comment . |
|---|---|---|---|---|---|
| Dinardo et al2 | Randomized frontline | OS, 14.7 months | Aza | OS, 9.6 months | Best response: IDH1, IDH2, FLT3, and NPM1 |
| Cherry et al4 | Retrospective frontline | OS, 884 days PMC, NR | IC | OS, 484 days PMC, 705 days | OS advantage in IC; but in PMC trend to OS advantage in Aza/VEN |
| Matthews et al6 | Retrospective frontline | OS, 11 months | CPX-351 | OS, 13 months | Longer HLOS and more infections in CPX-351 Arm |
| Pelland et al8 | RetrospectiveR/R | OS, 6.8 months | “other salvage” | OS, 11.2 months | No difference in infectious complications |
| Maiti et al5 | RetrospectiveR/R∗ | OS, 6.8 months | IC | OS, 4.7 months | |
| Unglaub et al1 | Retrospective | OS, 15.8 months Bridge to allo, 73% | Non-VEN salvage | OS, 10.5 months Bridge to allo, 63% | PMC showed trend to OS advantage of Aza-VEN |
| Study . | Trial type . | Aza/VEN response . | Comparator . | Comparator response . | Comment . |
|---|---|---|---|---|---|
| Dinardo et al2 | Randomized frontline | OS, 14.7 months | Aza | OS, 9.6 months | Best response: IDH1, IDH2, FLT3, and NPM1 |
| Cherry et al4 | Retrospective frontline | OS, 884 days PMC, NR | IC | OS, 484 days PMC, 705 days | OS advantage in IC; but in PMC trend to OS advantage in Aza/VEN |
| Matthews et al6 | Retrospective frontline | OS, 11 months | CPX-351 | OS, 13 months | Longer HLOS and more infections in CPX-351 Arm |
| Pelland et al8 | RetrospectiveR/R | OS, 6.8 months | “other salvage” | OS, 11.2 months | No difference in infectious complications |
| Maiti et al5 | RetrospectiveR/R∗ | OS, 6.8 months | IC | OS, 4.7 months | |
| Unglaub et al1 | Retrospective | OS, 15.8 months Bridge to allo, 73% | Non-VEN salvage | OS, 10.5 months Bridge to allo, 63% | PMC showed trend to OS advantage of Aza-VEN |
Allo, allogeneic bone marrow transplant; HLOS, hospital length of stay; NR, no response; OS, overall survival; PMC, propensity matched cohort.
Used 10-day decitabine rather than Aza in combination with VEN.